Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098318 · ClinicalTrials.gov registry record · Phase 3
Rhodiola Rosea Therapy of Major Depressive Disorder
A Phase 3 study of Depression, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT01098318: Completed Phase 3 study of Depression, sponsored by University of Pennsylvania.
NCT01098318 is a Phase 3 study of Depression that has completed, run by University of Pennsylvania. The registered enrollment target is 58 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01098318, a Phase 3 study of Depression, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
Primary Outcome
Hamilton Depression Rating Scale (HAM-D) is a validated, clinician-rated instrument for ascertaining the severity of MDD symptoms. The 28-item Hamilton Depression Rating Scale was used to determine the primary outcome of 17-item HAM-D score. The HAM-D will serves as the primary outcome measure. HAM-D17 score ranges from 0 to 68. Higher score indicates more depressed symptom.
Conditions Studied
Interventions
- DRUG Sertraline
- DIETARY_SUPPLEMENT Herbal extract
- OTHER Lactose monohydrate
Study Locations (1)
Pennsylvania
- Depression Research Unit - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT01098318 record still lists
NCT01098318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Sertraline is the first listed.
NCT01098318 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01098318 about?
NCT01098318 is a clinical study titled "Rhodiola Rosea Therapy of Major Depressive Disorder". Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
What is the current status of trial NCT01098318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2010-06. Estimated completion is 2013-07.
What conditions does trial NCT01098318 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01098318?
The interventions under investigation include: Sertraline (DRUG), Herbal extract (DIETARY_SUPPLEMENT), Lactose monohydrate (OTHER).
Who is sponsoring clinical trial NCT01098318?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01098318 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01098318's enrollment target sits among peer trials
58 449th of 679 higher than 230 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia